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ㅋ
Functional gastrointestinal disorder (FGID) is one of the commonest digestive diseases worldwide and leads to significant mor-
bidity and burden on healthcare resource. The putative bio-psycho-social pathophysiological model for FGID underscores the 
importance of psychological distress in the pathogenesis of FGID. Concomitant psychological disorders, notably anxiety and de-
pressive disorders, are strongly associated with FGID and these psychological co-morbidities correlate with severity of FGID 
symptoms. Early life adversity such as sexual and physical abuse is more commonly reported in patients with FGID. There is 
mounting evidence showing that psychological disorders are commonly associated with abnormal central processing of visceral 
noxious stimuli. The possible causal link between psychological disorders and FGID involves functional abnormalities in various 
components of the brain-gut axis, which include hypothalamic-pituitary-adrenal system, sympathetic and parasympathetic nerv-
ous system, serotonergic and endocannabinoid systems. Moreover, recent studies have also shown that psychological distress 
may alter the systemic and gut immunity, which is increasingly recognized as a pathophysiologic feature of FGID. Psychotropic 
agent, in particular antidepressant, and psychological intervention such as cognitive behavioral therapy and meditation have 
been reported to be effective for alleviation of gastrointestinal symptoms and quality of life in FGID patients. Further studies 
are needed to evaluate the impact of early detection and management of co-morbid psychological disorders on the long-term 
clinical outcome and disease course of FGID.
(J Neurogastroenterol Motil 2012;18:13-18)
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Introduction
Functional gastrointestinal disorder (FGID) is one of the 
commonest digestive disease entities, which is characterized by 
recurrent gastrointestinal symptoms with no identifiable organic 
pathology. In recent years, a bio-psycho-social pathophysiological 
model has been implicated for the pathogenesis of FGID, which 
emphasizes the importance of biological, social, environmental 
and psychological factors in development of FGID.
1 This paper 
aimed to review the epidemiology, mechanism and psychological 
intervention of FGIDs.Justin CY Wu
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Figure. Schematic diagram illustrating 
the pathophysiologic links between 
functional gastrointestinal disorder and 
psychiatric disorders. SERT, serotonin 
reuptake transporter; 5-HT, serotonin; 
HPA, hypothalamic-pituitary-adrenal; 
TRPV, transient receptor potential 
vanilloid; FGID, functional gastroin-
testinal disorder.
Epidemiological Association Between Func-
tional Gastrointestinal Disorder and Psycho-
logical Disorders
The observations on the association between psychological 
disorders and FGID used to be considered conflicting, and it was 
generally regarded as biased observations that were limited to 
more severe patients seen in referral center setting. An early study 
conducted in a gastroenterology clinic reported a very high life-
time prevalence of generalized anxiety disorder of 34% in newly 
referred irritable bowel syndrome (IBS) patients.
2 In another 
study that involved patients with anxiety or depressive disorders, 
IBS symptoms were found to be associated with severity of anxiety 
and depressive symptoms. However, patients with depression in 
remission had no associated IBS symptoms.
3 In a study of primary 
care patients referred for endoscopy, however, there was no differ-
ence between patients with functional or organic dyspepsia in the 
prevalence or risk of mental distress as determined by 
questionnaire.
4 Talley et al
5 reported that dyspepsia patients who 
present for investigation were more likely to be neurotic, anxious, 
and depressed than non-dyspepsia controls. Using the gold stand-
ard diagnostic method with psychiatrist-conducted structured 
Clinical Interview for Diagnostic Statistical Manual of Mental 
Disorders-IV Axis I Disorders, we have reported that anxiety dis-
orders are diagnosed in 38% of patients with functional dyspepsia 
compared with 4% in the general population.
6 Depression, anxi-
ety, phobia and somatization are strongly correlated with severity 
of dyspeptic symptoms in a group of patients from tertiary center.
7 
Somatization is more commonly seen in patients with co-morbid 
FGID and psychological disorder.
8 It has also been observed that 
IBS patients with psychiatric morbidity are characterized by low 
rectal distension pain thresholds, high rates of healthcare con-
sultations, interpersonal problems and sexual abuse.
9
In recent years, there are mounting evidence showing that 
similar association between FGIDs and psychological disorders 
also exists in the community and primary care setting, suggesting 
a genuine relationship between psychological co-morbidity and 
FGID rather than biased observations in referral centers. In a 
community-based study in Sweden, anxiety but not depression is 
linked to functional dyspepsia with postprandial distress syn-
drome but not to epigastric pain syndrome.
10 In a pop-
ulation-based study in Hong Kong, the prevalence of generalized 
anxiety disorder is significantly higher in subjects reporting IBS 
symptoms compared to those reporting these symptoms (16.5% 
vs 3.3%, P ＜ 0.001), and IBS is associated with 6-fold increase 
in the likelihood of having generalized anxiety disorder.
11 Anxiety 
is an independent factor in determining health care utilization in 
patients with dyspepsia and IBS.
12 In general practice setting, 
psychological distress is a major determinant of impaired health 
of patients with dyspepsia.
13,14 Similar to patients in referral cen-
ters, these primary care patients are also characterized by higher 
levels of depression and somatization.
15
Putative Mechanisms That Are Involved in 
the Association Between Functional Gastro-
intestinal Disorder and Psychological Disor-
ders
Despite the strong epidemiological association between Psychiatric Disorders and FGIDs
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FGID and psychological disorder, it may not imply a direct caus-
al relationship. Yet, there are cumulating evidence showing that 
the pathophysiology of FGID involves abnormal processing of 
visceral nociceptive signals in the brain-gut axis, which leads to 
visceral hypersensitivity and hyperalgesia.
16 Furthermore, FGID 
patients are also characterized by abnormalities in autonomic, 
neuroendocrine and immune functions (Figure). And all of these 
physiological functions are subjected to the influence of psycho-
logical distress in the “emotional motor system,” which is com-
prised of the visceral motor cortex, the amygdala, the hypo-
thalamic nuclei and the peri-aqueductal grey. This neural net-
work involves corticotrophin releasing factor (CRF) containing 
neuronal projections that activate both the autonomic nervous 
system and hypothalamus-pituitary-adrenal axis. The system is 
involved in a wide spectrum of physiological activities such as 
arousal, vigilance and pain modulation. Hyperactivity of the neu-
roendocrine and visceral perceptual response to physiological (eg, 
meal) or psychological stimuli may account for the stress-induced 
flare of bowel symptoms in IBS patients,
17,18 and administration 
of CRF alleviates visceral hyperalgesia and negative affective re-
sponse to bowel stimulation in IBS patients.
19 Increased be-
ta-adrenergic activity is significantly correlated with visceral hy-
persensitivity and symptoms of hard or lumpy stools in con-
stipation-predominant IBS.
20 It has also been reported that anxi-
ety induces gastric sensorimotor dysfunction and postprandial 
symptoms in patients with functional dyspepsia.
21
Psychological disorders and FGID also share common ge-
netic predispositions particularly the genes that are involved in se-
rotonergic activities. It has been shown that homozygous G-pro-
tein beta 3 C825T polymorphism is associated with functional 
dyspepsia. And this G protein polymorphism has also been linked 
to depression.
22 It has been reported that the polymorphism of se-
rotonin reuptake transporter (SERT) genes is associated with the 
subtypes of IBS.
23 Polymorphisms in the promoter for synthesis 
of SERT influence response to serotonergic medications in de-
pression as well as colonic transit response to alosetron, a seroto-
nin receptor-3 (5-HT3) antagonist, in patients with diarrhea pre-
dominant IBS.
24 A recent study has also reported that C/C geno-
type of the c.-42C＞T polymorphism in 5-HT3A receptor, com-
pared with T carrier status, is associated with increased anxiety 
and amygdala responsiveness as well as the severity of IBS 
symptoms.
25
Early life adversity, particularly psychological stress, has 
been speculated to play an important role of pathogenesis of 
FGID. It has been shown that self-reported sexual and physical 
abuse are more common in community and clinic subjects with 
gastrointestinal symptoms such as IBS and functional dys-
pepsia.
26-28 Other social and environmental factors, such as ex-
posure to war time conditions, infantile and childhood trauma, 
and social learning of illness behavior are predictors of the IBS in 
adulthood.
29,30 In animal models, it has been shown that early life 
psychological stress such as neonatal maternal separation results 
in the development of visceral hyperalgesia and anxiety features.
31 
There are a number of putative mechanisms that mediates the de-
velopment of these pathophysiologic changes induced by early 
life stress. These include hyper-responsiveness of serotonergic 
system in both central and enteric nervous systems,
32 increased 
sympathetic and decreased parasympathetic activities,
33 increased 
expression of CRF type 1 receptors and transient receptor ion 
channel 1 (TRPV1).
34,35 The resultant visceral hyperlagesia is 
likely related to central sensitization at both brain and spinal 
levels.
36,37
In recent years, a positive association between psychological 
stress and abnormal immunity has also been implicated in the 
pathophysiologic mechanism of IBS. IBS patients have coexist-
ing hyperactivity of the hypothalamic-pituitary-adrenal axis and 
increase in pro-inflammatory cytokine levels.
38 Chronic psycho-
logical stress leads to maladaptive increase in mucosal perme-
ability and decrease in secretory response of intestinal epithelium 
to luminal stimuli.
39 It has been shown that the change in in-
testinal mucosal permeability is mediated by CRF.
40
Psychotropic Treatment and Psychological 
Intervention of Functional Gastrointestinal 
Disorder
There is ample evidence supporting the therapeutic role of 
psychotropic agents in the treatment of FGID. Most of these tri-
als were conducted in patients with IBS and non-cardiac chest 
pain. Antidepressant is the most extensively evaluated psycho-
tropic agent for treatment of FGIDs. In the recent Cochrane 
Database Systematic Review, there is an unequivocal beneficial 
effect for antidepressants over placebo for improvement of ab-
dominal pain (54% for antidepressants compared to 37% of pla-
cebo: relative risk [RR], 1.49; 95% CI, 1.05-2.12; P = 0.03; 
number needed to treat [NNT] = 5), global assessment (59% 
for antidepressants compared to 39% of placebo: RR, 1.57; 95% 
CI, 1.23-2.00; P ＜ 0.001; NNT = 4) and symptom score (53% 
of antidepressants compared to 26% of placebo: RR, 1.99; 95% 
CI, 1.32-2.99; P = 0.001; NNT = 4).
41 Tricyclic antidepressant 
has been shown to attenuate stress induced visceral hyper-Justin CY Wu
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sensitivity with suppressed brain activation, suggesting a mecha-
nism of central pain modulating effect that is independent of anti-
depressive effect.
42 In patients with functional dyspepsia, ami-
triptyline has been shown to be superior to placebo in reducing 
dyspeptic symptom score especially nausea but there is no effect 
on drinking capacity and postprandial symptoms in the drink 
tests.
43
Selective serotonin reuptake inhibitor (SSRI), another class 
of antidepressant with superior safety and side effect profile, has 
been shown to reduce pain symptoms in patients with non-car-
diac chest pain in addition to IBS.
44 Acute administration of cit-
alopram leads to reduction in chemical and mechanical esoph-
ageal sensitivity in healthy volunteers.
45 SSRI reduces somatiza-
tion and improves affective response to chronic visceral pain.
46,47 
These effects are independent of its anti-depressive actions but 
patients who have concomitant anxiety or depression and somati-
zation tend to have better symptom response to psychotropic 
agents.
47,48 However, its therapeutic benefit in non-depressed 
IBS patients has not been substantiated.
49
The serotonin-norepinephrine reuptake inhibitor, or SNRI, 
is a newer class of antidepressant with faster onset of action in the 
treatment of depression. However, the use of SNRI in the treat-
ment of FGID is more conflicting. Its use in functional dyspepsia 
is limited by the lack of efficacy and gastrointestinal upset. It has 
been shown that venlafaxine is not superior to placebo for treating 
functional dyspepsia in a randomized controlled trial. Further-
more, there is a short-term worsening of dyspepsia.
50 Yet, ven-
lafaxine has been shown to be more effective than placebo in im-
proving pain control and emotional well-being in patients with 
non-cardiac chest pain in a small randomized controlled trial.
51
Apart from antidepressants, other psychotropic agents have 
also been evaluated for treatment of FGID. For example, the 
combination formulation of flupentixol and melitracen (Deanxit
Ⓡ) 
has been shown to be useful for acute symptom control of 
dyspepsia.
52 Trazodone has been shown to be useful for treatment 
of non-cardiac chest pain due to esophageal hypersensitivity.
53 
Pregabalin, a new class of drug known as alpha-2-delta ligand, 
increases distension sensory thresholds to normal levels in IBS 
patients with rectal hypersensitivity.
54
Despite the promising results on the efficacy, none of the 
above mentioned psychotropic agents have been approved by the 
regulatory authority such as FDA for the treatment of FGID. 
Therefore, these agents can only be used in patients with co-mor-
bid psychological disorders or as off-label use with consents ob-
tained from the patients.
In addition to the effectiveness in the management of anxiety 
and depressive disorders, psychological intervention alone or in 
combination with psychotropic agent has also been shown to be 
useful in treatment of patients with FGID. Cognitive behavioral 
therapy has been most extensively evaluated for treatment of 
FGID.
55 Psychodynamic-interpersonal psychotherapy has also 
been shown to be effective in alleviating dyspeptic symptoms, and 
the effects are enduring after cessation of the psychotherapy.
56 
Combination of sertraline and pain coping skill training has been 
shown to be more effective than either modality alone in the treat-
ment of non-cardiac chest pain.
57 In patients with refractory func-
tional dyspepsia, combination of intensified medical therapy with 
psychological intervention yields superior long-term-outcomes. 
Cognitive behavioral therapy gives additional benefits to con-
comitant anxiety and depression.
58 In a recent randomized con-
trolled trial, mindfulness training has a substantial therapeutic ef-
fect on bowel symptom severity, health-related quality of life, and 
reduces distress in IBS patients.
59
Conclusion
The strong association between psychological disorders and 
FGID has been increasingly recognized and there is mounting 
evidence that supports the causative relationship with biological 
plausibility. However, the detection and management of con-
comitant psychological disorder in patients with FGID remains 
far from satisfactory. Most patients lack the awareness of their 
psychological symptoms and most primary care clinicians and 
gastroenterologists lack the vigilance and skills in screening for 
these common co-morbid conditions. This invariably leads to de-
layed diagnosis and intervention as well as unnecessary inves-
tigations. A good doctor-patient rapport, therapeutic relationship 
and psychoeducation are essential so that psychological inter-
vention can be implemented with patient’s acceptance. Psycho-
tropic agents should be judiciously used in FGID patients with 
co-morbid psychological conditions as intolerance and poor ad-
herence are common owing to their lack of awareness and hyper-
vigilance to side effects. Further studies are needed to evaluate 
the impact of early detection and management of co-morbid psy-
chological disorders on the long-term clinical outcome and dis-
ease course of FGID.
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